5 Years Long Term Results After Standalone CyPass-Implantation
Retro- and Prospective Monocentric Study to Evaluate the Safety and Effectiveness of the CyPass Stent 5 Years After Implantation
調査の概要
詳細な説明
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Mecklenburg/Vorpommern
-
Neubrandenburg、Mecklenburg/Vorpommern、ドイツ、17036
- Dietrich-Bonhoeffer-Klinikum
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- patients who have undergone a standalone cypass implantation at least 3 years ago
- signed inform consent
Exclusion Criteria:
- Patients with too much travel distance between study center and home
- Patients who cannot visit the studycenter due to health problems
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
standalone CyPass implantation
patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
|
Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Patients That Achieve Target Intraocular Pressure Measured in mmHg
時間枠:up to 7 years
|
The Measurement of the intraocular Pressure is a criterion for the Efficacy of CyPass Stent Procedure (success rate).
The postoperative target pressure of 15 mmHg, 18 mmHg or 21 mmHg (depends on Glaucoma Status) has to be achieved.
|
up to 7 years
|
|
Change of Intraocular Pressure in mmHg Preoperatively (at Screening) vs Postoperatively (at Final Examination)
時間枠:up to 7 years
|
The Measurement of the intraocular Pressure change is a criterion for the Efficacy of CyPass Stent Procedure (success rate). The postoperative pressure after 5 to 7 years has to be compared with the preoperative intraocular pressure (in mmHg) The change was calculated only from two time points. (value at the final examination time point minus the value at the preoperative time point |
up to 7 years
|
|
Number of Additional Medication
時間枠:up to 7 years
|
The number of additional Glaucoma medication is another criterion to determine the Efficacy of CyPass Stent Procedure (success rate). Up to 4 different active substance can be used to reduce the pressure. The more substances the patient uses postoperatively the lower is the success after implantation of the CyPass-Stent. The postoperative number of medications after 5 years has to be compared with the preoperative number |
up to 7 years
|
|
Number of Participants With Secondary Glaucoma Procedures
時間枠:up to 7 years
|
To determine the efficacy of CyPass Stent procedure completely the number of secondary glaucoma interventions (surgery/ laser) has to be documented
|
up to 7 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Stability of Optic Nerve
時間枠:up to 7 years
|
The Measurement of the optic nerve (HRT) in comparison to the baseline is needed to evaluate the glaucoma damage and to determine the Longterm success rate and the safety of the CyPass- Stent-Procedure. With papillary tomography you can see the changes in the optic nerve head concerning the permanent failures of retinal vessels , measure them very precisely and compare them with the previous findings. |
up to 7 years
|
|
Number of Participants With Stability of the Retinal Nerve Fiber Layer Thickness
時間枠:up to 7 years
|
The comparison of the preoperative and postoperative Status of the Retinal Nerve Fiber Layer Thickness and retinal fundus thickness is another criterion to determine the absolute and relative success.
|
up to 7 years
|
|
Number of Participants With Stability of Visual Field
時間枠:up to 7 years
|
The parameter of the Visual Field (Mean Deviation) will be measured to evaluate the Safety of the CyPass-Procedure.
The visual Field shows the progression of glaucoma defects concerning failures in different parts for example in the center or in the periphery of the visual field.
|
up to 7 years
|
|
Number of Participants With Stability of Stent Position
時間枠:up to 7 years
|
Determination of Stent Position in the angle will be performed to exclude moving of the Stent.
The stent could change it's position forward into the anterior chamber or backwards in the suprachorioidal space
|
up to 7 years
|
|
Number of Participants With Stability of Stent Tissue Interaction
時間枠:up to 7 years
|
Determination of iris tissue reaction to the stent will be performed.
We document slight reaction without involving the opening, iris reaction with involving the opening and complete closure by tissue.
The iris Tissue could overgrow the opening of the stent and therfore the function of the stent is disturbed or even failed.
|
up to 7 years
|
|
Number of Participants With Intra-and Postoperative Complications
時間枠:up to 7 years
|
The number of intra-and postoperative complications are needed to evaluate the safety of the CyPass-procedure
|
up to 7 years
|
|
Number of Participants With Suprachoroidal Bleb
時間枠:up to 7 years
|
The Determination of the suprachoroidal bleb is needed to evaluate the function of the stent and the efficacy of the procedure.
The bigger the bleb, the lower the pressure and the better the efficacy of the stent
|
up to 7 years
|
協力者と研究者
捜査官
- 主任研究者:Helmut Hoeh, MD,FEBO、Department of Ophthalmology, Neubrandenburg, Germany
出版物と役立つリンク
一般刊行物
- Garcia-Feijoo J, Rau M, Grisanti S, Grisanti S, Hoh H, Erb C, Guguchkova P, Ahmed I, Grabner G, Reitsamer H, Shaarawy T, Ianchulev T. Supraciliary Micro-stent Implantation for Open-Angle Glaucoma Failing Topical Therapy: 1-Year Results of a Multicenter Study. Am J Ophthalmol. 2015 Jun;159(6):1075-1081.e1. doi: 10.1016/j.ajo.2015.02.018. Epub 2015 Mar 3.
- Hoeh H, Vold SD, Ahmed IK, Anton A, Rau M, Singh K, Chang DF, Shingleton BJ, Ianchulev T. Initial Clinical Experience With the CyPass Micro-Stent: Safety and Surgical Outcomes of a Novel Supraciliary Microstent. J Glaucoma. 2016 Jan;25(1):106-12. doi: 10.1097/IJG.0000000000000134.
- Grisanti S, Margolina E, Hoeh H, Rau M, Erb C, Kersten-Gomez I, Dick HB, Grisanti S. [Supraciliary microstent for open-angle glaucoma: clinical results of a prospective multicenter study]. Ophthalmologe. 2014 Jun;111(6):548-52. doi: 10.1007/s00347-013-2927-6. German.
- Hoh H, Grisanti S, Grisanti S, Rau M, Ianchulev S. Two-year clinical experience with the CyPass micro-stent: safety and surgical outcomes of a novel supraciliary micro-stent. Klin Monbl Augenheilkd. 2014 Apr;231(4):377-81. doi: 10.1055/s-0034-1368214. Epub 2014 Apr 25.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Glaucoma diagnosticsの臨床試験
-
MP Biomedicals, LLCMP Biomedicals Asia Pacific Pte. Ltd.完了HTLV-I感染症 | HTLV-II感染症 | ヒト T リンパ球向性ウイルス 1 | ヒト T リンパ向性ウイルス 2 | HTLV I 関連 T 細胞性白血病 リンパ腫 | HTLV I 関連ミエロパシーアメリカ
-
General Practitioners Research InstituteAstraZeneca募集息切れ | 心臓血管 | 精神疾患 | 肺オランダ, ポルトガル, スペイン
-
MP Biomedicals, LLCMP Biomedicals Asia Pacific Pte. Ltd.完了HTLV-I感染症 | HTLV-II感染症 | ヒト T リンパ球向性ウイルス 1 | ヒト T リンパ向性ウイルス 2 | HTLV I 関連 T 細胞性白血病 リンパ腫 | HTLV I 関連ミエロパシーアメリカ
-
Haukeland University HospitalSiemens Corporation, Corporate Technology完了
-
Stanford UniversitySanta Clara Valley Medical Center引きこもった